Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis
…, G Facondo, L Lo Faro, F Cuccia, G Vullo… - Clinical & Experimental …, 2021 - Springer
Adrenal metastases occur in 15–35% of oncological patients. Surgery is the first treatment
option. Stereotactic body radiotherapy (SBRT) has been largely explored in oligometastatic …
option. Stereotactic body radiotherapy (SBRT) has been largely explored in oligometastatic …
[HTML][HTML] Androgen receptor targeted therapy+ radiotherapy in metastatic castration resistant prostate cancer
M Massaro, G Facondo, G Vullo, AM Aschelter… - Frontiers in …, 2021 - frontiersin.org
Objectives To investigate whether radiotherapy as metastasis-directed therapy (MDT) on
oligo-progressive sites in metastatic castration-resistant prostate cancer (mCRPC) patients …
oligo-progressive sites in metastatic castration-resistant prostate cancer (mCRPC) patients …
[HTML][HTML] Stereotactic body radiation therapy boost in patients with cervical cancer ineligible for brachytherapy
G Facondo, G Vullo, V DE SANCTIS… - Cancer Diagnosis & …, 2021 - ncbi.nlm.nih.gov
… GIUSEPPE FACONDO, # GIANLUCA VULLO, # VITALIANA DE SANCTIS, MAURIZIO
VALERIANI, ANNA MARIA ASCOLESE, MARIA MASSARO, DIMITRI ANZELLINI, and …
VALERIANI, ANNA MARIA ASCOLESE, MARIA MASSARO, DIMITRI ANZELLINI, and …
[HTML][HTML] Image-guided moderately hypofractionated radiotherapy for localized prostate cancer: a multicentric retrospective study (IPOPROMISE)
…, S Gomellini, S Scoccianti, M Stefanacci, G Vullo… - La radiologia …, 2024 - Springer
Background Moderate hypofractionated radiotherapy is a treatment option for the cure of
localized prostate cancer (PCa) patients based on the results of randomized prospective trials, …
localized prostate cancer (PCa) patients based on the results of randomized prospective trials, …
[HTML][HTML] Efficacy of Residual Site Radiation Therapy (ISRT) in Patients with Primary Mediastinal Lymphoma with Deauville Score 4 Following R-CHT: Results of a …
G Facondo, M Serio, G Vullo, MP Bianchi… - Journal of Clinical …, 2023 - mdpi.com
Background: In order to evaluate the efficacy of residual site radiation therapy (RSRT) in
terms of progression-free survival (PFS) and overall survival (OS) in patients with primary …
terms of progression-free survival (PFS) and overall survival (OS) in patients with primary …
[HTML][HTML] Clinical outcomes and toxicity of CT-guided high dose-rate brachytherapy in women with locally-advanced cervical cancer
V DE SANCTIS, G Facondo, G Vullo… - Cancer Diagnosis & …, 2023 - ncbi.nlm.nih.gov
Background/Aim: To evaluate the outcome and toxicities in patients with locally advanced
cervical cancer (LACC) treated with radiochemotherapy and intracavitary brachytherapy. …
cervical cancer (LACC) treated with radiochemotherapy and intracavitary brachytherapy. …
[HTML][HTML] Hypofractionated radiotherapy in intermediate-risk prostate cancer patients: Long-term results
M Valeriani, M Di Staso, G Facondo, G Vullo… - Journal of Clinical …, 2022 - mdpi.com
Background: To evaluate outcomes in terms of survival and toxicity in a series of intermediate-risk
prostate cancer (PCa) patients treated with hypofractionated radiotherapy (HyRT) + …
prostate cancer (PCa) patients treated with hypofractionated radiotherapy (HyRT) + …
[HTML][HTML] Fiducial markers in adjuvant setting for a patient affected by endometrial cancer: a case report
F Titone, S Restaino, E Moretti, G Vullo, A Poli… - Frontiers in …, 2023 - frontiersin.org
Introduction Intermediate-high and high-risk endometrial cancer often require adjuvant
treatments such as radiotherapy (RT) or brachitherapy (BT) to reduce the risk of loco-regional …
treatments such as radiotherapy (RT) or brachitherapy (BT) to reduce the risk of loco-regional …
[HTML][HTML] Comparative analysis of toxicity in patients with anal cancer undergoing definitive simultaneous integrated boost (SIB) or sequential integrated boost (SeqB) …
M Rotondi, G Facondo, S Mossa, G Vullo… - International Journal of …, 2023 - Springer
… Stefano Mossa and Gianluca Vullo data curation, Giuseppe Facondo and Gianluca Vullo
writing, … Ilaria Aangelicone, Giuseppe Facondo and Gianluca Vullo prepared tables. All authors …
writing, … Ilaria Aangelicone, Giuseppe Facondo and Gianluca Vullo prepared tables. All authors …
[HTML][HTML] Stereotactic body radiation therapy (SBRT) for patients with oligometastatic/oligoprogressive adrenal metastases: Outcomes and toxicities profile in a …
G Facondo, G Vullo, M Valeriani, AM Ascolese… - Cancer Treatment and …, 2021 - Elsevier
Aims To evaluate survival outcomes and toxicology profiles in oligometastatic/oligoprogressive
patients treated with SBRT for adrenal metastases. Methods We retrospectively analyzed …
patients treated with SBRT for adrenal metastases. Methods We retrospectively analyzed …